ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
4 hedge funds and large institutions have $145K invested in ELITE PHARMACEUTICAL in 2014 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
18% less capital invested
Capital invested by funds: $176K → $145K (-$31K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIA
Guyasuta Investment Advisors
Pittsburgh,
Pennsylvania
|
+$9K |
| 2 |
GA
Geneva Advisors
Chicago,
Illinois
|
+$3.34K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GA
1
Geneva Advisors
Chicago,
Illinois
| $93K | +$3.34K | +10,450 | +4% |
|
2
Janney Montgomery Scott
Philadelphia,
Pennsylvania
| $24.1K | – | – | – |
|
|
JAFL
3
Jay A. Fishman Ltd
Troy,
Michigan
| $19.3K | – | – | – |
|
|
GIA
4
Guyasuta Investment Advisors
Pittsburgh,
Pennsylvania
| $9K | +$9K | +30,000 | New |
|
ELI Hedge Fund Activity: Q3 2014 in Review
4 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q3 2014, worth a combined $145K — down 18% from $176K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ELI positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Guyasuta Investment Advisors, opening a new position worth an estimated $9K.
- 4 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q3 2014, up from 3 in Q2 2014.
- Funds reported $145K of ELITE PHARMACEUTICAL stock for Q3 2014, down 18% quarter-over-quarter.
- 1 fund opened new ELITE PHARMACEUTICAL positions in Q3 2014 and 0 closed out, a net change of +1 holder.
- The largest ELITE PHARMACEUTICAL buyer in Q3 2014 was Guyasuta Investment Advisors, an estimated $9K added.
Based on aggregated 13F filings for Q3 2014.